UPDATE - Climb Bio to Present at Upcoming September 2025 Investor Conferences

Climb Bio, Inc. (Nasdaq: CLYM), a biotechnology company focused on developing therapeutics for immune-mediated diseases, has announced that its executive team will participate in several investor conferences slated for September 2025. This initiative reflects the company's ongoing commitment to engage with the investment community and share updates on its clinical progress.

The company will kick off its conference participation at the Cantor Global Healthcare Conference on September 5, 2025, at 10:55 a.m. ET in New York City, featuring a fireside chat and one-on-one meetings. Following that, Climb Bio will be present at the Baird Global Healthcare Conference on September 9, 2025, at 4:20 p.m. ET, also in New York, with a similar format. The firm will then attend the Morgan Stanley Annual Global Healthcare Conference on September 10, 2025, which will be exclusively for one-on-one meetings.

In addition, Climb Bio will partake in the Stifel Virtual Immunology and Inflammation Forum on September 16, 2025, at 10:30 a.m. ET, which will include a presentation alongside one-on-one investor correspondences. Live webcasts of these events will be made available in the "Investors and News" section of Climb Bio's website, along with replays that can be accessed approximately two hours post-event and archived for at least 30 days.

Climb Bio's portfolio includes significant treatments under development, such as budoprutug, an anti-CD19 monoclonal antibody aimed at addressing a range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently undergoing IND-enabling studies for IgA nephropathy. This proactive communication strategy may enhance investor confidence and awareness as Climb Bio continues to advance its clinical-stage pipeline.

As Climb Bio, Inc. (Nasdaq: CLYM) gears up to present at multiple investor conferences in September 2025, investors should take note of the company's strategic positioning in the clinical-stage biotechnology sector, particularly in developing therapeutics for immune-mediated diseases. Climb Bio's participation in high-profile events such as the Cantor Global Healthcare Conference and the Baird Global Healthcare Conference signals its ongoing commitment to maintaining transparency and engaging with potential investors.

Key catalysts for Climb Bio include its promising clinical pipeline, especially the anti-CD19 monoclonal antibody, budoprutug, which has shown significant potential in treating a variety of B-cell mediated diseases. Additionally, the advancement of CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy, further corroborates the company's innovative approach in addressing commonly overlooked conditions. Investors should be attentive to the details disclosed during these presentations, as any updates or data regarding clinical trials could influence market sentiment and valuation.

The timing of these conferences is fortuitous, coinciding with a broader recovery narrative in the biotechnology sector as regulatory environments stabilize and investment flows begin to normalize post-pandemic. Moreover, the transition to virtual formats, as seen in the Stifel Virtual Immunology and Inflammation Forum, offers a broad reach, allowing institutional and retail investors alike to engage directly.

For investors looking at Climb Bio, the upcoming conferences represent a critical opportunity to assess the management team's strategic vision and gain insights into the trajectory of its therapeutics. Monitoring how the market responds to the information disclosed during these events can offer valuable insights for positioning in this dynamic and rapidly evolving sector. Given the clinical successes and innovative prospects, CLYM could emerge as a compelling investment opportunity for those interested in biotech ventures.